Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.
News|Articles|April 9, 2026
ASCO Thyroid Cancer Guideline Updates Synthesize Evidence-Based Systemic Therapy Recommendations
Author(s)Ashling Wahner
Fact checked by: Riley Kandel, Kirsty Mackay
ASCO has published updates to the clinical practice guidelines for the use of systemic therapy across subsets of patients with thyroid cancer.
Advertisement
Advertisement
On April 1, 2026, the American Society of Clinical Oncology (ASCO) published new clinical practice guidelines with evidence-based recommendations for the use of systemic therapy across thyroid cancer subtypes.1 Read on for a snapshot of the most pertinent updates.
Related to this article
Updated phase 2 LINKER-SMM1 data show single-agent, fixed-duration linvoseltamab produced deep, durable, and MRD-negative responses in high-risk smoldering multiple myeloma.
The FDA has approved lirafugratinib (Lyrfigtu) for the treatment of adult patients with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 gene fusion or other rearrangement.
An IDMC recommended continuing a phase 2 minimal residual disease study of IMNN-001 without modification following a favorable safety review.
Shailender Bhatia, MD, discusses next steps for adjuvant therapy research in light of the phase 3 ADAM trial data and broader implications for Merkel cell carcinoma.
Clinicians and researchers are set to gather for the UCSF-cosponsored International Invasive Lobular Carcinoma Symposium.
SOT106 now holds both orphan drug and fast track designations across soft tissue sarcoma and osteosarcoma ahead of a first-in-human trial.
Shailender Bhatia, MD, discusses ADAM trial design, key efficacy and safety findings, and treatment implications in Merkel cell carcinoma.
Advertisement
Advertisement